PMID- 34083274
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 41
IP  - 6
DP  - 2021 Jun
TI  - HLA-DR and CD74 Expression and the Immune Microenvironment in Renal Cell 
      Carcinoma.
PG  - 2841-2848
LID - 10.21873/anticanres.15065 [doi]
AB  - BACKGROUND/AIM: Expression of human leukocyte antigen (HLA) class I and II and 
      CD74, which functions as a chaperone of MHC class II, play essential roles in 
      T-cell recognition. The aim of this study was to elucidate the association 
      between the HLAs and CD74, and their correlation with the infiltrated immune 
      cells in renal cell carcinoma (RCC). MATERIALS AND METHODS: We retrospectively 
      investigated the expression of HLA-A/B/C, HLA-DR, and CD74 in 38 patients with 
      advanced RCC (T3/T4), and evaluated their correlations with CD4 and CD8-positive 
      T-cell infiltration using immunohistochemistry. RESULTS: The expression of 
      HLA-A/B/C, HLA-DR, and CD74 on cancer cells was observed in 37, 20, and 31 
      patients, respectively. The density of CD8- and CD4-positive T cells showed a 
      positive correlation with HLA-DR expression. The density of CD4-positive 
      lymphocytes was significantly associated with CD74 expression. CONCLUSION: The 
      expression of HLA-DR, rather than CD74, on cancer cells was potentially 
      associated with the anti-cancer immune microenvironment.
CI  - Copyright (c) 2021 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Miura, Yuji
AU  - Miura Y
AD  - Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto 
      University, Kumamoto, Japan.
AD  - Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
FAU - Anami, Toshiki
AU  - Anami T
AD  - Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto 
      University, Kumamoto, Japan.
AD  - Department of Urology, Graduate School of Medical Sciences, Kumamoto University, 
      Kumamoto, Japan.
FAU - Yatsuda, Junji
AU  - Yatsuda J
AD  - Department of Urology, Graduate School of Medical Sciences, Kumamoto University, 
      Kumamoto, Japan.
FAU - Motoshima, Takanobu
AU  - Motoshima T
AD  - Department of Urology, Graduate School of Medical Sciences, Kumamoto University, 
      Kumamoto, Japan.
FAU - Oka, Suguru
AU  - Oka S
AD  - Department of Urology, Toranomon Hospital, Tokyo, Japan.
FAU - Suyama, Koichi
AU  - Suyama K
AD  - Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
FAU - Inoshita, Naoko
AU  - Inoshita N
AD  - Department of Pathology, Toranomon Hospital, Tokyo, Japan.
FAU - Kinowaki, Keiichi
AU  - Kinowaki K
AD  - Department of Pathology, Toranomon Hospital, Tokyo, Japan.
FAU - Urakami, Shinji
AU  - Urakami S
AD  - Department of Urology, Toranomon Hospital, Tokyo, Japan.
FAU - Kamba, Tomomi
AU  - Kamba T
AD  - Department of Urology, Graduate School of Medical Sciences, Kumamoto University, 
      Kumamoto, Japan.
FAU - Komohara, Yoshihiro
AU  - Komohara Y
AD  - Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto 
      University, Kumamoto, Japan; ycomo@kumamoto-u.ac.jp.
AD  - Center for Metabolic Regulation of Healthy Aging, Kumamoto University, Kumamoto, 
      Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antigens, Differentiation, B-Lymphocyte)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (invariant chain)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Differentiation, B-Lymphocyte/*immunology
MH  - Carcinoma, Renal Cell/*immunology
MH  - Female
MH  - HLA-DR Antigens/*immunology
MH  - Histocompatibility Antigens Class II/*immunology
MH  - Humans
MH  - Kidney Neoplasms/*immunology
MH  - Male
MH  - Middle Aged
MH  - *Tumor Microenvironment
OTO - NOTNLM
OT  - HLA-DR
OT  - RCC
OT  - TAM
OT  - TIL
OT  - microenvironment
EDAT- 2021/06/05 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/06/04 06:05
PHST- 2021/02/17 00:00 [received]
PHST- 2021/05/19 00:00 [revised]
PHST- 2021/05/20 00:00 [accepted]
PHST- 2021/06/04 06:05 [entrez]
PHST- 2021/06/05 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 41/6/2841 [pii]
AID - 10.21873/anticanres.15065 [doi]
PST - ppublish
SO  - Anticancer Res. 2021 Jun;41(6):2841-2848. doi: 10.21873/anticanres.15065.